Home > Boards > US Listed > Medical - Healthcare >

Xenetic Biosciences Inc. (XBIO)

Add XBIO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 4/26/2019 2:39:27 PM - Followers: 18 - Board type: Free - Posts Today: 0

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. Xenetic's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer. Further, Xenetic's proprietary drug development platform, PolyXen, enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The Company has ongoing business development activities to explore partnerships utilizing its PolyXen delivery platform.

FLOAT                                        2.29M
% Held by Insiders 1 75.11%
% Held by Institutions 1 0.39%

As of 14 June 2018


We incorporate our patented and proprietary technologies into a number of drug candidates currently under development either in-house or with biotechnology and pharmaceutical collaborators in order to create what we believe will be the next-generation of biologic drugs and therapeutics. While we primarily focus on researching and developing orphan oncology drugs, we also have significant ownership or other economic interests in drugs being developed by our collaborators.


PolyXen is a patent-protected enabling platform technology designed for protein or peptide therapeutics. It uses the natural polymer polysialic acid (PSA) to prolong a drug's circulating half-life and potentially improve other pharmacological properties. PolyXen has been demonstrated in human clinical trials to confer extended half-life to biotherapeutics such as recombinant human erythropoietin and recombinant Factor VIII (rFVIII).

XBIO-101 (sodium cridanimod)

XBIO-101 is a small-molecule immunomodulator and interferon inducer which, in preliminary studies, has been shown to increase progesterone receptor (PrR) expression in endometrial tissue. The Company has exclusive rights to develop and commercialize XBIO-101 worldwide, except for specified countries in the Commonwealth of Independent States, including Russia. XBIO-101 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of progesterone receptor negative (PrR-) endometrial cancer in conjunction with progesterone therapy. XBIO-101 is currently being studied in an ongoing Phase 2 clinical trial. Patient enrollment for the Phase 2 trial commenced in June 2017.

  • The primary objective of the open-label, multi-center, single-arm, two-period Phase 2 study is to assess the antitumor activity of XBIO-101 in conjunction with progestin therapy as measured by Overall Disease Control Rate in women with recurrent or persistent endometrial carcinoma not amenable to surgical treatment or radiotherapy who have either failed progestin monotherapy or who have been identified as PrR-. Secondary objectives include assessments of efficacy and safety/tolerability
    The study is expected to enroll a total of 72 women with recurrent or persistent endometrial cancer not amenable to surgical treatment or radiotherapy but suitable to be treated with progestins. All subjects determined to be PrR- at screening, as well as those subjects who experience disease progression after at least 4 weeks of progestin monotherapy, will receive XBIO-101 in combination with continued progestin treatment. Subjects will receive treatment until disease progression as defined according to RECIST 1.1 criteria.


Key Executives

Name Title Pay Exercised Year Born
Mr. Jeffrey F. Eisenberg CEO, Pres & Director 44.81k N/A 1966
Mr. James F. Parslow CFO, COO & Corp. Sec. N/A N/A 1965
Dr. Curtis A. Lockshin Chief Scientific Officer N/A N/A 1960

Transfer Agent


Shareholders of Record   424
Latest 10Q



Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#1402   XBIO up at 1.57..still oversold Blutribe 04/26/19 02:39:27 PM
#1401   XBIO, oversold here at 1.40, last IPO 3/5 Blutribe 04/26/19 11:25:26 AM
#1400   https://finance.yahoo.com/news/xenetic-biosciences-announces-pricing-3-142700154 Chappy86 03/05/19 10:02:28 AM
#1399   XBIO HUGE NEWS OUT >>> On March 4, l2 hunter 03/04/19 08:29:00 AM
#1398   $10 ? reality $ 2.22 reggabnet 02/22/19 11:44:34 AM
#1397   I understand toybaby 02/07/19 12:36:45 PM
#1396   toybaby, I have a free account and can't Citrati 02/07/19 12:20:18 PM
#1395   This stock is way overdue for news of Kabuli 01/03/19 05:13:52 PM
#1394   extremely quiet today toybaby 12/13/18 11:17:29 AM
#1393   November 16 will give us the news we need toybaby 11/05/18 11:51:47 AM
#1392   could be. XBIO with strong technical setting and l2 hunter 10/22/18 03:46:32 PM
#1391   News Soon ? toybaby 10/22/18 10:55:14 AM
#1390   toybaby 09/28/18 02:17:24 PM
#1389   Yes The announcement holds the answer It toybaby 09/28/18 02:17:16 PM
#1388   I hope they announced something positive about the Kabuli 09/28/18 01:36:30 PM
#1387   I am sticking with XBIO this new toybaby 09/28/18 09:54:45 AM
#1386   ARE SHELF OFFERINGS GOOD OR BAD? https://www.redchip.com/index.php?/news/16/are-shelf-registr Chappy86 09/28/18 09:24:39 AM
#1385   MIXED SHELF OFFERING The ability to offer securities Chappy86 09/28/18 09:22:51 AM
#1384   Shelf Offering Chappy86 09/28/18 09:19:30 AM
#1383   What is a MIXED Shelf Offering? toybaby 09/28/18 07:00:58 AM
#1382   Agreed bobl17211 09/26/18 04:07:33 PM
#1381   We don't need them SOOOO If they come toybaby 09/26/18 04:04:24 PM
#1380   It appears the pumpers came through and left Chappy86 09/26/18 03:22:39 PM
#1379   Yes That it Does! toybaby 09/25/18 11:19:18 AM
#1378   Orchestrated push that suddenly went limp? However, it Chappy86 09/25/18 10:27:14 AM
#1377   XBIO going in position for strong close im l2 hunter 09/24/18 01:59:43 PM
#1376   Back on bid here. Curt D 09/24/18 01:23:37 PM
#1375   Yeah let’s see... I also got 15k now... europtiger 09/24/18 01:10:31 PM
#1374   Going back up today imo. No one want l2 hunter 09/24/18 11:47:22 AM
#1373   Got a huge load around gapfill... let’s see lol europtiger 09/24/18 11:37:17 AM
#1372   $10 Analyst Buy Target for XBIO not without l2 hunter 09/24/18 10:19:18 AM
#1371   XBIO is on the move again! Good call! Curt D 09/24/18 10:17:54 AM
#1370   Thx... and same to you europtiger 09/24/18 10:15:51 AM
#1369   Good luck! I just jumped into a different stock. Curt D 09/24/18 10:10:28 AM
#1368   I just got first order filled 3;60´s Maybe gapfill... europtiger 09/24/18 10:08:26 AM
#1367   Nice! I sold too quickly this morning, but Curt D 09/24/18 10:06:48 AM
#1366   Got out 4,38 average... maybe buying back soon europtiger 09/24/18 10:04:54 AM
#1365   Agreed bobl17211 09/24/18 09:22:28 AM
#1364   XBIO first SQUEEZE ahead? l2 hunter 09/24/18 09:10:34 AM
#1363   Decent close. Holding a lot of it's gains. Curt D 09/21/18 04:04:59 PM
#1361   ++ XBIO-101 milestone FDA News ahead now? huge l2 hunter 09/21/18 03:16:54 PM
#1360   what is the next support and Resistance Level RusselHustle 09/21/18 02:46:21 PM
#1359   I haven't found any yet but if there Chappy86 09/21/18 02:19:32 PM
#1358   Monday premarket could be good also. Curt D 09/21/18 01:31:01 PM
#1357   If it runs to hod eod,I will hold europtiger 09/21/18 01:28:48 PM
#1356   That would be great! I would be tempted Curt D 09/21/18 01:27:25 PM
#1355   Let’s have a nice Friday hod close europtiger 09/21/18 01:25:00 PM
#1354   Spread is tightening up and the bid is building. Curt D 09/21/18 01:19:47 PM
#1353   And here we go europtiger 09/21/18 01:18:10 PM
#1352   Löw float Saison starting I am fully loaded europtiger 09/21/18 01:17:50 PM